Quince Therapeutics, Inc.
QNCX
$34.04
$1.635.03%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 17.39% | 10.79% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -31.56% | 42.87% | |||
| Operating Income | 31.56% | -42.87% | |||
| Income Before Tax | 184.20% | -169.22% | |||
| Income Tax Expenses | -269.71% | 6,939.13% | |||
| Earnings from Continuing Operations | 191.01% | -193.54% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 191.01% | -193.54% | |||
| EBIT | 31.56% | -42.87% | |||
| EBITDA | 31.62% | -42.98% | |||
| EPS Basic | 150.74% | -184.41% | |||
| Normalized Basic EPS | 140.93% | -190.91% | |||
| EPS Diluted | 140.63% | -184.41% | |||
| Normalized Diluted EPS | 140.61% | -190.91% | |||
| Average Basic Shares Outstanding | 63.79% | 3.19% | |||
| Average Diluted Shares Outstanding | 65.05% | 3.19% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||